For years, essential tremor has been managed with medications first developed for other conditions. That may be about to change. Ulixacaltamide, a selective T-type calcium channel modulator from Praxis Precision Medicines, reported positive results from two pivotal Phase 3 studies — the Essential3 program, described as the first positive Phase 3 program in essential tremor — measuring its effect on patients' ability to perform daily activities. It has received FDA Breakthrough Therapy Designation, and a new drug application was submitted in 2026 (Praxis Precision Medicines, 2026). It is investigational and not yet approved, but if it clears review it would be the first new medication approved specifically for essential tremor in decades — a genuine milestone.
Deep brain stimulation already works well for severe tremor, and the next step is making it responsive. Adaptive (closed-loop) DBS senses the brain's electrical activity in real time and adjusts stimulation automatically, instead of running continuously — which can sharpen control, reduce side effects and extend battery life. Adaptive DBS was FDA-approved for Parkinson's disease in 2025. For essential tremor specifically it is still investigational, studied in closed-loop research that uses cortical sensing to deliver stimulation on demand — in one study, achieving effective tremor suppression with roughly half the energy of continuous stimulation (Opri et al., Sci Transl Med, 2020).
Incisionless focused ultrasound thalamotomy is already established for treating tremor on one side of the body. The emerging step is treating both sides in staged sessions. An open-label clinical trial reported that staged, bilateral focused ultrasound thalamotomy was feasible in medication-refractory essential tremor, with adverse events that were mostly mild (Kaplitt & Krishna et al., JAMA Neurol, 2024). This is genuinely promising for people whose tremor affects both hands, but bilateral treatment carries different risks than one-sided treatment, and for now it is available mainly through specialist centres and studies rather than routinely.
The wearable-device space has moved quickly. The Encora X1, a prescription wrist neurostimulation device for essential tremor, received FDA clearance in February 2026, joining the next-generation Cala kIQ line among recently cleared options (Encora Therapeutics, 2026). Beyond the cleared products, feasibility studies of other wearable approaches for essential tremor are ongoing. For a detailed head-to-head of the wearables you can actually buy today, see the device comparison linked below.
Botulinum toxin injections have long been used for some tremor, particularly of the head and voice, but dosing hand tremor without causing weakness has been difficult. Recent work on individualized onabotulinumtoxinA injection patterns for upper-limb essential tremor reported positive Phase 2 results in 2025 — an effort to make the approach more precise. It remains investigational for this use.
Pipeline news is worth following, but it's easy to misread. A few practical habits help:
- Anchor on stage. "Phase 3" and "FDA-approved" are very different from "early study" or "preclinical." The stage tells you how close something realistically is.
- Ask your neurologist what's relevant to you specifically; a movement-disorder specialist often knows which trials are recruiting nearby.
- Use ClinicalTrials.gov to look up trials by condition and location, and read the eligibility criteria before getting hopeful.
- Don't put current care on hold. Proven medications, procedures, therapy and available devices manage tremor today; the pipeline is about tomorrow, not a reason to wait.
The encouraging headline is real: after decades of little movement, essential tremor and Parkinson's tremor are seeing meaningful innovation across drugs, stimulation, ultrasound and wearables at the same time. Just read each development for what it actually is — and check where it stands with your specialist before pinning hopes on it.